Center for Precision Medicine, Department of Internal Medicine, Section on Molecular Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, 27157 NC, USA.
Clin Chem Lab Med. 2020 Jun 25;58(6):939-947. doi: 10.1515/cclm-2019-0130.
The goal of advancing science in health care is to provide high quality treatment and therapeutic opportunities to patients in need. This is especially true in precision medicine, wherein the ultimate goal is to link disease phenotypes to targeted treatments and novel therapeutics at the scale of an individual. With the advent of -omics technologies, such as genomics, proteomics, microbiome, among others, the metabolome is of wider and immediate interest for its important role in metabolic regulation. The metabolome, of course, comes with its own questions regarding technological challenges. In this opinion article, I attempt to interrogate some of the main challenges associated with individualized metabolomics, and available opportunities in the context of its clinical application. Some questions this article addresses and attempts to find answers for are: Can a personal metabolome (n = 1) be inexpensive, affordable and informative enough (i.e. provide predictive yet validated biomarkers) to represent the entirety of a population? How can a personal metabolome complement advances in other -omics areas and the use of monitoring devices, which occupy our personal space?
推进医疗保健科学的目标是为有需要的患者提供高质量的治疗和治疗机会。在精准医学中尤其如此,其最终目标是将疾病表型与针对个体的靶向治疗和新型疗法联系起来。随着组学技术(如基因组学、蛋白质组学、微生物组学等)的出现,代谢组学因其在代谢调节中的重要作用而引起了更广泛和直接的关注。代谢组学当然也存在与其相关的技术挑战。在这篇观点文章中,我试图探讨与个体化代谢组学相关的一些主要挑战,以及在其临床应用背景下的可用机会。本文旨在回答并尝试寻找答案的问题有:一个人的代谢组(n=1)是否可以既经济实惠又信息量丰富(即提供具有预测性但经过验证的生物标志物),足以代表整个人群?个人代谢组如何补充其他组学领域的进展和监测设备的使用,这些设备占据着我们的个人空间?